BEIJING, March 6 -- China has expanded and optimized the utilization of drugs and therapies in the treatment of the novel coronavirus disease (COVID-19) to block the conversion of mild cases to severe cases and save critically ill patients.
Tocilizumab, with the common brand name Actemra, has been included in China's latest version of diagnosis and treatment guidelines on COVID-19.
Zhou Qi, deputy secretary-general and an academician of the Chinese Academy of Sciences, said at a press conference Friday that the drug Tocilizumab has been found effective to block the inducement of the inflammatory storm.
In an initial clinical trial, Tocilizumab was used in 20 severe COVID-19 cases. And the body temperatures of all the patients dropped within one day. Nineteen of the patients were discharged from the hospital within two weeks, and one got better, according to Zhou.
Currently, the drug is under clinical trials in 14 hospitals in Wuhan, the epicenter of the epidemic, Zhou said.
As of March 5, a total of 272 severe patients had been treated with Tocilizumab.
In addition to Tocilizumab, Chloroquine Phosphate and some traditional Chinese medicines, as well as convalescent plasma therapy, have been included in the treatment guideline. China is also pushing forward the utilization of some advanced technologies such as stem cell and monoclonal antibody technologies in the treatment of severe cases, said Wu Yuanbin, director-general of science and technology for social development of the Ministry of Science and Technology (MOST).
The drug Chloroquine Phosphate has been used in treating 285 critically ill COVID-19 patients in a hospital in Wuhan, and no obvious adverse reactions have been found so far, said Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the MOST.
Two clinical trials for Remdesivir are ongoing, and we are looking forward to seeing the results, Sun said.
The combination of traditional Chinese medicines and Western medicines has shown good results in the treatment of COVID-19. Statistics show that 90 percent of the patients in Hubei Province have been treated with traditional Chinese medicines, Sun said.
2009年4月18日雅思写作权威预测
2009年4月25日雅思口语考试预测(全国)
2009年4月雅思A/G类写作预测
雅思口语4月重点话题预测
2009年4月18日雅思听力预测—曾丽娟
2009年2月28日雅思考试预测——翡翠冰糖版
09年2月7号雅思考试预测
2009年2月28日雅思考试全面预测
2009年3月14日雅思A/G类考试全面权威预测
2009年2月28日雅思听力预测
2009年2月28日雅思口语预测
2月21和28日雅思全面预测和复习重点
2009年2月28日雅思大作文预测
2009年3月21日雅思写作权威预测
2009年5月16日雅思听力预测—曾丽娟
2009年3月雅思A/G类写作预测
2009年雅思考试趋势预测:听力题型
2009年3月5/7日雅思考试预测——翡翠冰糖版
2009年3月14日郑州考区雅思口语考试预测
2009年3月14日雅思考试全面预测
2009年3月5日/7日雅思口语权威预测
2009年3月雅思写作权威预测
2009年3月21日雅思听力预测
2009年4月18日雅思口语预测—曾丽娟
2009年雅思考试趋势预测:听力难度和策略
2009年3月7日雅思写作预测
2009年3月21日雅思考试预测——翡翠冰糖版
2009年4月18日雅思考试预测——翡翠冰糖版
2009年4月18日雅思A/G类考试全面权威预测—叶毅斌
2009年3月14日雅思听力预测
不限 |
英语教案 |
英语课件 |
英语试题 |
不限 |
不限 |
上册 |
下册 |
不限 |